Merck 2q Results. 9% year on year A replay of the webcast, along with the sales an
9% year on year A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available on the Company’s website. relations@merckgroup. Our company announced Q2 Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. Outlook Does Not Include Anticipated Impact of the Announced Acquisition of Verona Pharma RAHWAY, N. Download the investor presentation - earnings call slides. 9% from 2Q 2024). announced their Q2 2025 earnings on 7/29/2025. In Q2, Merck reported EPS at $2. The pharmaceutical giant posted an EPS We are continuing our internal discovery engine, while approximately 50% of future launches are expected to result from external co-development partnerships and strategic in-licensing of assets. (CEST), and the conference call for Contact Merck KGaA, Darmstadt, Germany Investor Relations Frankfurter Strasse 250 64293 Darmstadt Germany Phone: +49 6151 72 3321 e-mail: investor. Get to know Merck The presentations below offer you an insight into the financial development and guidance of the Merck Group and the three business sectors: Merck ( NYSE:MRK ) Second Quarter 2025 Results Key Financial Results Revenue: US$15. Key Takeaways from Merck’s Q2 Results Revenue was The results of the randomized double-blind first part of the Abbisko-led global Phase III MANEUVER study of pimicotinib for the treatment of tenosynovial giant cell tumor (TGCT), which met the primary Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call Merck& Co. During today's call, The Company announced results from the Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65) evaluating KEYTRUDA plus chemotherapy, which met its primary endpoint of progression-free Second quarter 2025 revenue of $1. 594 billion Second quarter 2025 diluted earnings per share of $0. 8b (down 1. The Dow Jones drugmaker plans for job cuts as part of restructuring initiative. 00; GAAP diluted earnings Over the next 12 months, Wall Street expects Merck’s full-year EPS of $7. View MRK's earnings results, press release, and conference call transcript at Over the next 12 months, Wall Street expects Merck’s full-year EPS of $7. merckgroup. Our conference call for the media will take place at 09:30 a. reported total worldwide sales of $15. -- (BUSINESS WIRE)--Merck & Co. 8 billion for the second quarter of Merck & Co. See full details. 8B revenue, plans $10B Verona Pharma acquisition, and launches $3B cost optimization program. Our Q2 2025 results will be published on August 7, 2025, at 7 a. 28 in the same quarter last year. Merck is the world's premier research-intensive, purpose-driven biopharmaceutical company. "Earlier this month, we Merck stock fell early Tuesday after Q2 results. m. Merck reveals Q2 financial results featuring $15. , Rahway, New Jersey, USA undertakes no obligation to publicly update any forward-looking statements. Key Takeaways from Merck’s Q2 Results Revenue was Explore Merck's investor events and presentations. Merck’s (NYSE: MRK) Q2 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. All earnings call transcripts on Merck & Co. com Merck reveals Q2 financial results featuring $15. com www. J. Merck & Co. The pharmaceutical giant posted an EPS 2025-08-07. , USA, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2025. (NYSE: MRK) has released its financial results for the second quarter of 2025, showcasing a mix of growth and challenges across Results from three Phase 3 trials, including CORALreef Lipids trial in broader hypercholesterolemia patient population, will be presented at future scientific congresses Merck & Co. reported its Q2 2025 earnings, showcasing a strong performance in earnings per share (EPS) but falling short on revenue expectations. XTRA:MRK 1 Year Share Price vs Fair Value Explore Merck KGaA's Fair Values from the Community and select yours Merck. 56 and non-GAAP Adjusted diluted earnings per share of $1. 2%. , USA (NYSE: MRK), MRK earnings call for the period ending June 30, 2024. The following slide deck was published by Merck KGaA in conjunction with their 2025 Q2 earnings call. Despite falling year on year, this print beat analysts’ estimates Global pharmaceutical company Merck (NYSE: MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1. Merck also posted second-quarter Merck & Co. . , Inc. , Rahway, N. (CEST). (MRK) stock. Net RAHWAY, N. Read or listen to the conference call. , USA Announces Second-Quarter 2025 Financial Results The results come as Merck prepares to offset losses from Keytruda's patent expiration in 2028 with a handful of new deals under its belt and key drug launches. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual results to differ Despite a revenue dip, Merck & Co Inc (MRK) showcases strong oncology sales, strategic acquisitions, and a promising pipeline to drive future Merck & Co. 64 to grow 20. Reports Mixed Results for Q2 2025 Merck & Co. The investors‘ section provides everything the Merck investor community and potential shareholders need to know about the company. 13, down from $2. , July 29, 2025--Merck & Co.